

Prescriber Information

| | | | | | | |
|------------------|--|-----------------------------------|----|--------|----|------|
| Prescriber Name: | | MD | DO | NP | PA | NPI: |
| Office Contact: | | Practice Name / Collaborating MD: | | | | |
| Address: | | City: | | State: | | Zip: |
| Phone: | | Fax: | | | | |

Patient Information • PLEASE SEND COPY OF INSURANCE CARD

| | | | | | | | |
|-------------------------|---|-----------------------|----------------|----------|--------------|---------|---------------|
| Patients Name: | | Last 4 Digits of SS#: | DOB: / / | Sex: M F | Weight: | Height: | Diabetic? Y N |
| Address: | | City: | | State: | | Zip: | |
| Home Phone: | | Work/Cell: | HIPAA Contact: | | Emergency #: | | |
| Interpreter Needed? Y N | Allergies: Y N If Yes, list allergies: | | | | | | |

Insurance Information

| | | | | |
|--------------------|------------|-----------------------|------|------|
| Primary Insurance: | Policy ID: | Group #: | BIN: | PCN: |
| Policyholder Name: | | Policyholder DOB: / / | | |

Clinical Information • PLEASE SEND COPY OF MEDICAL AND PRESCRIPTION INSURANCE CARDS, PROGRESS NOTES AND LAB REPORTS, SUPPORTING DIAGNOSIS, CO-MORBIDITIES AND LAB VALUES

| | | | | | |
|--|------------------------|--|-------------------------|-------------------------------|-----------------------------|
| ICD-10/Diagnosis Code: | Alopecia areata (L63) | Psoriasis Vulgaris (L40.0) | Other Psoriasis (L40.8) | Psoriasis unspecified (L40.9) | Psoriatic Arthritis (L40.5) |
| Hidradenitis Suppurativa (L73.2) Chronic Urticaria (L50.8) Atopic Dermatitis (L20.9) Basal cell carcinoma (C44.) Other: | | | | | |
| TB/PDD Test Given: Y N | Date of Neg. Test: / / | HBV Positive? Y N If Yes, is patient currently treated? Y N | | | |
| Prior Treatment? Y N (Provide Information Below) | BSA Affected (%): | Affected Areas: Palms Soles Head Neck Genitalia Other: | | | |
| Prior Therapy: | | Reason for Discontinuation of Therapy: | | | Approx. Start Date: / / |
| | | | | | Approx. End Date: / / |
| Comorbidities: | | Concomitant Medications: | | | |

Prescription Information

| Medication | Quantity/Dose | Sig | Refills |
|--|---|---|-------------------|
| ADBRY™ | 1 carton (4x150mg/mL) | Starter Dose: Inject 600mg (four 150mg injections) SQ at week 0. Begin maintenance dosing at week 2. | No Refills |
| | 1 carton (2x150mg/mL) 1 carton (4x150mg/mL) | Maintenance Dose: Inject 300mg (two 150mg injections) SQ every other week Inject 300mg (two 150mg injections) SQ every 4 weeks | |
| BIMZELX® PFS Pen | 1 carton (2x160mg/mL) | Starter Dose: Inject 320mg (two 160mg injections) SQ at weeks 0, 4, 8, 12 and 16 | 4 |
| | 1 carton (2x160mg/mL) | Maintenance Dose: Inject 320mg (two 160mg injections) SQ every 8 weeks Inject 320mg (two 160mg injections) SQ every 4 weeks | |
| CIBINQO™ | 50mg tablet (30 day supply) 100mg tablet (30 day supply) 200mg tablet (30 day supply) | Take 1 tablet by mouth daily | |
| CIMZIA® PFS Vials | 1 starter kit (6x200mg/ml) | Starter Dose: Inject 400mg SQ at weeks 0, 2 and 4 | No Refills |
| | 1 carton (2x200mg/mL) 2 cartons (4x200mg/mL) | Maintenance Dose: Inject 400mg SQ every 4 weeks Inject 200mg SQ every 2 weeks Inject 400mg SQ every other week (plaque psoriasis only) Inject 200mg SQ every other week | |
| COSENTYX® <i>*Pediatrics (age 6 & older)</i> | 4 cartons (4x75mg/0.5ml) PFS 4 cartons (4x150mg/ml) PFS 4 cartons (4x150mg/ml) PEN | Starter Dose: Weight < 50kg: Inject 75mg SQ at weeks 0, 1, 2, and 3 Weight ≥ 50kg: Inject 150mg SQ at weeks 0, 1, 2, and 3 | No Refills |
| | 1 carton (1x75mg/0.5ml) PFS 1 carton (1x150mg/ml) PFS 1 carton (1x150mg/ml) PEN | Maintenance Dose: Weight < 50kg: Inject 75mg SQ every 4 weeks beginning on Day 29 Weight ≥ 50kg: Inject 150mg SQ every 4 weeks beginning on Day 29 | |
| COSENTYX® <i>*Adults</i> PFS Sensoready® Pen/Unoready® Pen | 4 cartons (4x300mg/2mL) 4 cartons (8x150mg/mL) 4 cartons (4x150mg/mL) | Starter Dose: Inject 300 mg SQ at weeks 0, 1, 2, and 3 Inject 150 mg SQ at weeks 0, 1, 2, and 3 | No Refills |
| | 1 carton (1x300mg/2mL) 1 carton (2x150mg/mL) 1 carton (1x150mg/mL) | Maintenance Dose: Inject 300 mg SQ every 4 weeks beginning on Day 29 Inject 300 mg SQ every 2 weeks beginning on Day 29 Inject 150 mg SQ every 4 weeks beginning on Day 29 | |

Injection Training

| | | |
|-------------------------------------|---|---|
| Patient received injection training | Prescriber's office to provide injection training | Meijer to coordinate injection training |
|-------------------------------------|---|---|

By signing this form and utilizing our services, you are authorizing Meijer and its employees to serve as your prior authorization designated agent in dealing with medical and prescription insurance companies.

| | | | |
|----------------------|------|----------------------|------|
| Prescriber Signature | Date | Prescriber Signature | Date |
|----------------------|------|----------------------|------|

Substitution Permitted

Dispense as Written